INDIVIOR PHARMACEUTICALS INC

Indivior’s near‑completion of its Supernus Pharma acquisition signals a strategic shift toward specialty therapeutics, promising a potential rebound amid small‑cap consolidation.

Indivior’s shares barely edge up, staying below their 200‑day average and 52‑week range—highlighting the need for a stronger growth strategy.

Indivior (INDV) rose 2.66% to $34.79, beating peers like Erasca and Travere. See key metrics, moving averages, and 24‑hour stock insights.

Indivior stock rises 4.38 % to $34.77 as investors eye the October 29 Q3 earnings—could boost the drug‑addiction firm toward its 52‑week high.